Survival of patients with stage IIIC and IIID melanomas
with nodal metastases in the light of new therapies

Marcin Ziętek; Marcin Zdzienicki; Jędrzej Wierzbicki; Bożena Cybulska-Stopa; Maria Krotewicz; Wojciech Łobaziewicz; Wojciech M. Wysocki; Grażyna Kamińska-Winciorek; Maria Turska-d’Amico; Piotr Rutkowski

doi:10.5114/ada.2022.119971

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2022
vol. 39

Send email

Copy url:

abstract:

Original paper

Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies

Marcin Ziętek

^{1, 2}

,

Marcin Zdzienicki

³

,

Jędrzej Wierzbicki

^{1, 2, 4}

,

Bożena Cybulska-Stopa

⁵

,

Maria Krotewicz

³

,

Wojciech Łobaziewicz

⁶

,

Wojciech M. Wysocki

^{7, 8, 9}

,

Grażyna Kamińska-Winciorek

¹⁰

,

Maria Turska-d’Amico

¹¹

,

Piotr Rutkowski

³

Department of Oncology, Wroclaw Medical University, Wroclaw, Poland
Department of Surgical Oncology, Lower Silesian Oncology Pulmonology and Hematology Center, Wroclaw, Poland
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska Curie-National Research Institute of Oncology, Warsaw, Poland
Laboratory of Immunopathology, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland
Department of Surgical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland
Chair of Surgery, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Kracow University, Krakow, Poland
Department of General, Oncological and Vascular Surgery, 5th Military Clinical Hospital, Krakow, Poland
Maria Sklodowska-Curie National Research Institute of Oncology, Scientific Editorial Office, Warsaw, Poland
Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
Department of Oncological and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland

Adv Dermatol Allergol 2022; XXXIX (6): 1141-1150

DOI: https://doi.org/10.5114/ada.2022.119971

Online publish date: 2022/10/03

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Ziętek M, Zdzienicki M, Wierzbicki J, et al. Survival of patients with stage IIIC and IIID melanomas
with nodal metastases in the light of new therapies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2022;39(6):1141-1150. doi:10.5114/ada.2022.119971.

APA

Ziętek, M., Zdzienicki, M., Wierzbicki, J., Cybulska-Stopa, B., Krotewicz, M.,  & Łobaziewicz, W. et al. (2022). Survival of patients with stage IIIC and IIID melanomas
with nodal metastases in the light of new therapies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 39(6), 1141-1150. https://doi.org/10.5114/ada.2022.119971

Chicago

Ziętek, Marcin, Marcin Zdzienicki, Jędrzej Wierzbicki, Bożena Cybulska-Stopa, Maria Krotewicz, Wojciech Łobaziewicz,  and Wojciech M. Wysocki et al. 2022. "Survival of patients with stage IIIC and IIID melanomas
with nodal metastases in the light of new therapies". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 39 (6): 1141-1150. doi:10.5114/ada.2022.119971.

Harvard

Ziętek, M., Zdzienicki, M., Wierzbicki, J., Cybulska-Stopa, B., Krotewicz, M., Łobaziewicz, W., Wysocki, W., Kamińska-Winciorek, G., Turska-d’Amico, M.,  and Rutkowski, P. (2022). Survival of patients with stage IIIC and IIID melanomas
with nodal metastases in the light of new therapies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 39(6), pp.1141-1150. https://doi.org/10.5114/ada.2022.119971

MLA

Ziętek, Marcin et al. "Survival of patients with stage IIIC and IIID melanomas
with nodal metastases in the light of new therapies." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 39, no. 6, 2022, pp. 1141-1150. doi:10.5114/ada.2022.119971.

Vancouver

Ziętek M, Zdzienicki M, Wierzbicki J, Cybulska-Stopa B, Krotewicz M, Łobaziewicz W et al. Survival of patients with stage IIIC and IIID melanomas
with nodal metastases in the light of new therapies. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2022;39(6):1141-1150. doi:10.5114/ada.2022.119971.

Introduction
Within stage III melanoma prognosis and outcomes significantly vary. Advances in systemic therapy improved prognosis in metastatic melanoma. Adjuvant therapy in stage III significantly lowered relapses, although the effect on survival is less evident. Analysis of treatment results in stage IIIC and IIID before introduction of the modern adjuvant therapy, but after introduction of the effective systemic therapy in metastatic relapse, is needed. Aim: To analyse the clinical outcomes in patients with stage IIIC and IIID melanoma before the introduction of the novel adjuvant therapy.

Material and methods
Consecutive stage IIIC and IIID melanoma patients treated in 2015–2018 in 4 reference centres in Poland were enrolled in the analysis of RFS and OS (in-transit metastases excluded). Median follow-up was 26.6 months (1.7–67.2).

Results
There were 224 stage IIIC and 49 stage IIID patients. Recurrence was observed in 170 (62.2%); 102 (45.5%) deaths in stage IIIC and 28 (57.1%) in stage IIID were reported. RFS and OS were better in stage IIIC compared to stage IIID. RFS and OS in the IIIC group were 19.7 and 36.2 months, respectively, and in IIID – 8.9 and 27.8 months, respectively.

Conclusions
The survival of patients with high-risk melanomas has improved in recent years, however, it is still unsatisfactory. The major changes in melanoma management related to the introduction of the adjuvant therapy require further careful observation.

keywords:

Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies

Marcin Ziętek 1, 2 , Marcin Zdzienicki 3 , Jędrzej Wierzbicki 1, 2, 4 , Bożena Cybulska-Stopa 5 , Maria Krotewicz 3 , Wojciech Łobaziewicz 6 , Wojciech M. Wysocki 7, 8, 9 , Grażyna Kamińska-Winciorek 10 , Maria Turska-d’Amico 11 , Piotr Rutkowski 3

stage III melanoma, systemic therapy, adjuvant therapy, immunotherapy, targeted therapy